Oral Session 1-13D Transplant Outcomes (2)

[OS1-13D-1] Allogeneic HCT for patients with Philadelphia chromosome-positive AML: a JSHCT AML WG study

Shohei Mizuno¹, Masamitsu Yanada², Koji Kawamura³, Motonori Mizutani¹, Masayoshi Masuko⁴, Naoyuki Uchida⁵, Yukiyasu Ozawa⁶, Koji Iwato⁷, Kazuteru Ohashi⁸, Kazuhiro Ikegame⁹, Sung-Won Kim¹⁰, Heiwa Kanamori¹¹, Tetsuya Eto¹², Yoshinobu Kanda³, Takahiro Fukuda¹⁰, Yoshiko Atsuta^13,14, Shingo Yano¹⁵, Akiyoshi Takami¹ (1.Division of Hematology, Department of Internal Medicine, Aichi Medical University, 2.Department of Hematology and Cell Therapy, Aichi Cancer Center, 3.Division of Hematology, Saitama Medical Center, Jichi Medical University, 4.Division of Stem Cell Transplantation, Niigata University Hospital, 5.Department of Hematology, Toranomon Hospital, 6.Department of Hematology, Japanese Red Cross Nagoya First Hospital, 7.Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 8.Hematology Division, Komagome Hospital, 9.Division of Hematology, Hyogo College of Medicine, 10.Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 11.Department of Hematology, Kanagawa Cancer Center, 12.Department of Hematology, Hamanomachi Hospital, 13.Japanese Data Center for Hematopoietic Cell Transplantation, 14.Department of Healthcare Administration, Nagoya University Graduate School of Medicine, 15.Department of Oncology and Hematology, Jikei University School of Medicine)